Opportunities in the Neurogenomics Market

 


Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

Opportunities in the Neurogenomics Market, Executive SummaryValuations of The Genomics EnterpriseValuations of The Genomics EnterpriseSummary of Major Findings in Each Therapeutic ClassAlzheimer's DiseaseParkinson's DiseaseMultiple SclerosisEpilepsyMigraineObesityMajor DepressionSchizophreniaConclusionsConclusionsOpportunities in the Neurogenomics Market, Research Methodology; Industry Challenges and OpportunitiesScope and Research MethodologyScope and Research MethodologyIdentification of Challenges and Opportunities Facing NeurogenomicsIdentification of Challenges and Opportunities Facing NeurogenomicsChallenges and Opportunities Affecting the Emerging Market for NeurogenomicsChallenges and Opportunities Affecting the Emerging Market for NeurogenomicsIndustry Challenges: NeurogenomicsIndustry Opportunities: NeurogenomicsOpportunities in the Neurogenomics Market, Market Engineering Research for NeurogenomicsOverview of the Neurogenomics LandscapeThe Neurogenomics EnterpriseScope and Definition of NeurogenomicsAssessment of the Current State of NeurogenomicsMarket Opportunity AnalysisExamples of Market Models for Several Existing Alzheimer's Genomic TargetsCompetitive StructureOpportunities in the Neurogenomics Market, Strategic Evaluation of the Neurogenomics LandscapeThe Net Present Value (NPV) Approach for Quantifying Market OpportunitiesThe Net Present Value (NPV) Approach for Quantifying Market OpportunitiesThe Present Value of Future Therapeutics Opportunities in Neurogenomics The Present Value of Future Therapeutics Opportunities in Neurogenomics NPV Analysis of the Entire Neurogenomics SpaceNPV Analysis of the Entire Neurogenomics SpaceA Closer Look at the NPV for the Migraines Space with Varying Timelines and Discount RatesA Closer Look at the NPV for the Migraines Space with Varying Timelines and Discount RatesOpportunities in the Neurogenomics Market, Profiles of Selected NeurogenesOverviewOverviewAlzheimer Disease 3 (AD3)Alzheimer Disease 3 (AD3)Alzheimer Disease 4 (AD4)Alzheimer Disease 4 (AD4)Amyloid Precursor Protein (APP)Amyloid Precursor Protein (APP)Apolipoprotein E (ApoE)Apolipoprotein E (ApoE)PLCD1PLCD1alpha-2-macroglobin (A2M)alpha-2-macroglobin (A2M)Obese (ob)/Leptin (LEP)Obese (ob)/Leptin (LEP)Agouti Related Transcript (ART)Agouti Related Transcript (ART)Uncoupling Protein 2 (UCP 2)Uncoupling Protein 2 (UCP 2)Cholecystokinin Receptor (CCKBR)Cholecystokinin Receptor (CCKBR)Neuropeptide Y (NPY)Neuropeptide Y (NPY)Pro-Melanin-Concentrating Hormone (PMCH) GenePro-Melanin-Concentrating Hormone (PMCH) GeneCalcium Channel; Voltage-Dependent; P/Q type; alpha 1A subunit (CACNL1A4)Calcium Channel; Voltage-Dependent; P/Q type; alpha 1A subunit (CACNL1A4)Synuclein; alpha (SNCA)Synuclein; alpha (SNCA)ParkinParkinSerotonin Transporter Gene (SLC6A4)Serotonin Transporter Gene (SLC6A4)Cholinergic Receptor; Nicotinic; Alpha Polypeptide 4 (CHRNA4)Cholinergic Receptor; Nicotinic; Alpha Polypeptide 4 (CHRNA4)Cystatin B (CSTB)Cystatin B (CSTB)mtDNA tRNA-lys MutationmtDNA tRNA-lys MutationEpilepsy; Progressive with Mental Retardation (EPMR)Epilepsy; Progressive with Mental Retardation (EPMR)Epilepsy; Juvenile Myoclonic 1 (EJM1)Epilepsy; Juvenile Myoclonic 1 (EJM1)Electroencephalographic Variant Pattern 1 (EEGV1)Electroencephalographic Variant Pattern 1 (EEGV1)Epilepsy; Generalized; Idiopathic (EGI)Epilepsy; Generalized; Idiopathic (EGI)Potassium Channel; Voltage-Gated; Subfamily Q; Member 2 (KCNQ2)Potassium Channel; Voltage-Gated; Subfamily Q; Member 2 (KCNQ2)Epilepsy; Benign Neonatal 2 (EBN2 or KCNQ3)Epilepsy; Benign Neonatal 2 (EBN2 or KCNQ3)Neurotrophin-3 (NT-3)Neurotrophin-3 (NT-3)Opportunities in the Neurogenomics Market, Profiles of Strategically Targeted CompaniesProfiles of Strategically Targeted CompaniesProfiles of Strategically Targeted CompaniesOpportunities in the Neurogenomics Market, Database of Key Industry ParticipantsMarket Participants (Genomics Firms)Market Participants (Genomics Firms)Related Companies (Pharmaceutical)Related Companies (Pharmaceutical)




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.